Description
Carfilzomib is an anti-cancer drug indicated for use as a selective proteasome inhibitor for the treatment of:
Multiple Myeloma: Patients who have taken at least two prior therapies including treatment with Lenalidomide and Bortezomib.
Carfilzomib is an anti-cancer drug indicated for use as a selective proteasome inhibitor for the treatment of:
Multiple Myeloma: Patients who have taken at least two prior therapies including treatment with Lenalidomide and Bortezomib.
Carfilzomib should be given by the health care providers. It comes as a powder to be mixed with the liquid in order to inject it into veins.
Some most common adverse reactions include fever, chills, weakness, diarrhea, joint/bone pain, shortness of breath, vomiting, nausea, and dizziness.
Also, serious side effects include vision changes, chest pain, extreme tiredness, blood in the urine and confusion.
Is carfilzomib injection FDA-approved?
Carfilzomib is an anti-cancer medication used for the treatment of patients suffering from multiple myeloma.
In what form carfilzomib generally comes?